Results for tag: "Anti-LINGO-1"

The Anti-LINGO-1 market is a subset of the Central Nervous System Drugs market, focusing on drugs that target the LINGO-1 protein. LINGO-1 is a protein found in the central nervous system that plays a role in the development and maintenance of the myelin sheath, which is essential for proper nerve conduction. Drugs that target LINGO-1 have the potential to treat a variety of neurological diseases, including multiple sclerosis, spinal cord injury, and stroke. Several companies are currently developing Anti-LINGO-1 drugs, including Biogen, Novartis, and Sanofi. Biogen is developing a monoclonal antibody, BIIB033, which is currently in Phase 2 clinical trials. Novartis is developing a small molecule, CEP-32496, which is in Phase 1 clinical trials. Sanofi is developing a monoclonal antibody, SAR442168, which is in preclinical development. Show Less Read more